Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(18 sites)
United States
University of Miami, Miami, Florida University of Michigan, Ann Arbor, Michigan Providence Cancer Institute, Portland, Oregon Pennsylvania Hospital, Philadelphia, Pennsylvania Belgium
Universitair Ziekenhuis Antwerpen, Antwerp Institut Jules Bordet, Brussels Cliniques Universitaires Saint-Luc, UCL Ouvain, Brussels Universitair Ziekenhuis Gent, Ghent Denmark
Rigshospitalet, Copenhagen Italy
Istituto Clinico Humanitas, Milan Isituto Europeo di Oncologia (IEO), Milan Spain
Hospital Universitari Vall d'Hebron, Barcelona Institut Catala d'Oncologia, L'Hospitalet de Llobregat (ICO), Barcelona Hospital 12 de Octubre, Madrid Hospital Universitari i Politecnic La Fe, Valencia Instituto de Investigacion Sanitaria (INCLIVA), Valencia United Kingdom
Royal Marsden Hospital, Sutton, London